Bentiromide
Chymex (bentiromide) is a small molecule pharmaceutical. Bentiromide was first approved as Chymex on 1983-12-29.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bentiromide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CHYMEX | Savage Laboratories | N-018366 DISCN | 1983-12-29 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
71 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Paroxysmal hemoglobinuria | D006457 | Orphanet_447 | D59.12 | 2 | 6 | 2 | — | — | 9 |
| Fibrous dysplasia of bone | D005357 | Orphanet_249 | M27.8 | 1 | 1 | 1 | — | 5 | 8 |
| Polyostotic fibrous dysplasia | D005359 | Orphanet_562 | Q78.1 | 1 | 1 | 1 | — | 4 | 7 |
| Hemoglobinuria | D006456 | — | R82.3 | 2 | 5 | 1 | — | — | 7 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | 1 | — | — | 2 |
| Syndrome | D013577 | — | — | 1 | — | 1 | — | — | 2 |
| Hemolysis | D006461 | — | — | — | — | 2 | — | — | 2 |
| Acromegaly | D000172 | — | — | — | — | 1 | — | — | 1 |
| Idiopathic pulmonary fibrosis | D054990 | — | J84.112 | — | — | 1 | — | — | 1 |
| Pulmonary fibrosis | D011658 | — | J84.10 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glomerulonephritis | D005921 | — | N05 | — | 4 | — | — | — | 4 |
| Fibrosis | D005355 | — | — | 1 | 2 | — | — | 1 | 3 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | 1 | — | — | 2 | 3 |
| Membranoproliferative glomerulonephritis | D015432 | — | — | — | 3 | — | — | — | 3 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 2 | — | — | — | 2 |
| Coronary artery disease | D003324 | — | I25.1 | 1 | 1 | — | — | — | 2 |
| Angina pectoris | D000787 | EFO_0003913 | I20 | 1 | 1 | — | — | — | 2 |
| Iga glomerulonephritis | D005922 | EFO_0004194 | — | — | 2 | — | — | — | 2 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 1 | — | — | — | 1 |
| Interstitial lung diseases | D017563 | EFO_0004244 | J84.9 | — | 1 | — | — | — | 1 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 20 | — | — | — | — | 20 |
| Renal insufficiency | D051437 | — | N19 | 2 | — | — | — | — | 2 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | — | — | — | — | 1 |
| Coronary disease | D003327 | — | — | 1 | — | — | — | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | — | — | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | — | — | — | — | 1 |
| Infarction | D007238 | EFO_0009463 | — | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pelvic floor disorders | D059952 | — | — | — | — | — | — | 4 | 4 |
| Urinary incontinence | D014549 | — | R32 | — | — | — | — | 2 | 2 |
| Stress urinary incontinence | D014550 | — | — | — | — | — | — | 2 | 2 |
| Dystonic disorders | D020821 | — | G24 | — | — | — | — | 2 | 2 |
| Dystonia | D004421 | — | — | — | — | — | — | 2 | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 2 | 2 |
| Leukemia | D007938 | — | C95 | — | — | — | — | 1 | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | — | — | — | 1 | 1 |
| Myeloid leukemia | D007951 | — | C92 | — | — | — | — | 1 | 1 |
| Enuresis | D004775 | — | R32 | — | — | — | — | 1 | 1 |
Show 19 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bentiromide |
| INN | bentiromide |
| Description | Bentiromide is the dipeptide obtained by condensation of N-benzoyl-L-tyrosine with 4-aminobenzoic acid. Used as a noninvasive screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy, it is given by mouth: the amount of 4-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas. It has a role as a diagnostic agent, an indicator and a reagent. |
| Classification | Small molecule |
| Drug class | antihyperlipidemic, thyromimetic derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 37106-97-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200368 |
| ChEBI ID | 31263 |
| PubChem CID | 6957673 |
| DrugBank | DB00522 |
| UNII ID | 239IF5W61J (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,774 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use